Updates

News from CinPressa

Follow CinPressa's progress as CIN-111 advances through development.

CinPressa has not issued any announcements yet. The first updates will appear here.

Media enquiries

Let’s advance medicine, together.

Stay connected with CinPressa

For partnering, investment, or general inquiries, connect with the team through our Contact page.

Advancing a best-in-class, long-acting AGT siRNA (CIN-111) for a durable backbone of blood pressure control.

Parent company

© 2026 CinPressa Pharma. All rights reserved.

A CinRx Pharma portfolio company